XERIS Pharmaceuticals Inc (XERS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:XERIS Pharmaceuticals Inc (XERS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8069
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
XERIS Pharmaceuticals Inc (XERIS) is a specialty pharmaceutical company that develops and commercializes injectable and infusible drug formulations. The company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of ultra concentrated formulations of proteins, peptides, antibodies and small molecules using syringes, multi-dose pens, auto-injectors and pumps. Its products are used for various therapeutic areas, including severe hypoglycemia, post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure, exercise-induced hypoglycemia, acute repetitive seizures and type 1/type 2 blood sugar control. The company caters caregivers, health practitioners and patients. XERIS is headquartered in Chicago, Illinois, the US.

XERIS Pharmaceuticals Inc (XERS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
XERIS Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
XERIS Pharma Raises USD10 Million in Series C Equity Financing 12
Xeris Pharma Raises Additional USD30 Million in Series C Financing 13
Xeris Pharma Raises Additional USD4 Million in Venture Financing 15
Xeris Pharmaceuticals Raises USD41 Million in Series C Financing Round 16
Xeris Pharma Raises USD7.3 Million in Series B Financing 17
XERIS Pharma Raises USD0.2 Million in Venture Financing 18
Partnerships 19
XERIS Pharma Enters into Agreement with Asahi Kasei Pharma 19
Juvenile Diabetes Research Partners with Xeris Pharma and LATITUDE Pharma 20
Equity Offering 21
Xeris Pharma Raises USD98.3 Million in IPO of Shares 21
Xeris Pharma Raises USD13 Million in Private Placement of Preferred Shares 22
XERIS Pharmaceuticals Inc – Key Competitors 23
XERIS Pharmaceuticals Inc – Key Employees 24
XERIS Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Aug 13, 2018: Xeris Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Highlights 26
Corporate Communications 27
Sep 07, 2017: Xeris Pharmaceuticals Appoints John P. Schmid to Board of Directors 27
Jan 09, 2017: Xeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEO 28
Product News 29
06/16/2017: Xeris Pharmaceuticals Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development Program 29
02/15/2018: Xeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia 31
Clinical Trials 32
Aug 17, 2018: Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris’ Novel Ready-to-Use Liquid Glucagon 32
Jul 18, 2018: Altasciences Participates in Clinical Trial for Type 1 Diabetes Mellitus 33
Jun 25, 2018: Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen 34
Feb 08, 2018: FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals’ Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH) 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
XERIS Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
XERIS Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XERIS Pharma Raises USD10 Million in Series C Equity Financing 12
Xeris Pharma Raises Additional USD30 Million in Series C Financing 13
Xeris Pharma Raises Additional USD4 Million in Venture Financing 15
Xeris Pharmaceuticals Raises USD41 Million in Series C Financing Round 16
Xeris Pharma Raises USD7.3 Million in Series B Financing 17
XERIS Pharma Raises USD0.2 Million in Venture Financing 18
XERIS Pharma Enters into Agreement with Asahi Kasei Pharma 19
Juvenile Diabetes Research Partners with Xeris Pharma and LATITUDE Pharma 20
Xeris Pharma Raises USD98.3 Million in IPO of Shares 21
Xeris Pharma Raises USD13 Million in Private Placement of Preferred Shares 22
XERIS Pharmaceuticals Inc, Key Competitors 23
XERIS Pharmaceuticals Inc, Key Employees 24

List of Figures
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
XERIS Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[XERIS Pharmaceuticals Inc (XERS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ChemAxon Kft:医療機器:M&Aディール及び事業提携情報
    Summary ChemAxon Kft (ChemAxon) is a provider of software platforms. The company provides chemistry and biology software solutions and consultancy services that help in optimizing the value of chemistry information in life sciences and research and development. Its product portfolio consists of desk …
  • SonaCare Medical LLC-医療機器分野:企業M&A・提携分析
    Summary SonaCare Medical LLC (SonaCare Medical), formerly US HIFU LLC is a medical device company that manufactures minimally invasive high intensity focused ultrasound (HIFU) surgical ablation systems for urological indications. The company's products include sonablate 450 and sonatherm. It offers …
  • ROHM Co Ltd (6963):企業の財務・戦略的SWOT分析
    ROHM Co Ltd (6963) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • University of Texas MD Anderson Cancer Center:企業の戦略的SWOT分析
    University of Texas MD Anderson Cancer Center - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Arca Continental SAB de CV:戦略・SWOT・企業財務分析
    Arca Continental SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Arca Continental SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Liebherr-International AG:企業の戦略・SWOT・財務分析
    Liebherr-International AG - Strategy, SWOT and Corporate Finance Report Summary Liebherr-International AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Applebee’s Restaurants LLC:企業の戦略・SWOT・財務情報
    Applebee's Restaurants LLC - Strategy, SWOT and Corporate Finance Report Summary Applebee's Restaurants LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • freenet AG:企業のM&A・事業提携・投資動向
    freenet AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's freenet AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Airest S.p.A.:企業の戦略・SWOT・財務分析
    Airest S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Airest S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • University College London Hospitals NHS Foundation Trust:企業の戦略的SWOT分析
    University College London Hospitals NHS Foundation Trust - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key …
  • Land Securities Group Plc:企業のM&A・事業提携・投資動向
    Land Securities Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Land Securities Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • PACCAR Inc.:企業の戦略・SWOT・財務情報
    PACCAR Inc. - Strategy, SWOT and Corporate Finance Report Summary PACCAR Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Shadin Avionics LP:企業の戦略・SWOT・財務分析
    Shadin Avionics LP - Strategy, SWOT and Corporate Finance Report Summary Shadin Avionics LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Oxurion NV (THR):製薬・医療:M&Aディール及び事業提携情報
    Summary Oxurion NV(Oxurion) formerly known as ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreo …
  • The E. W. Scripps Company:企業の戦略・SWOT・財務分析
    The E. W. Scripps Company - Strategy, SWOT and Corporate Finance Report Summary The E. W. Scripps Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • B2W – Companhia Global Do Varejo:企業の戦略・SWOT・財務分析
    B2W - Companhia Global Do Varejo - Strategy, SWOT and Corporate Finance Report Summary B2W - Companhia Global Do Varejo - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Epigenomics AG (ECX):企業の製品パイプライン分析
    Summary Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi pro …
  • Living Cell Technologies Ltd (LCT):企業の財務・戦略的SWOT分析
    Living Cell Technologies Ltd (LCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Star Gas Partners L.P.
    Star Gas Partners L.P. - Strategy, SWOT and Corporate Finance Report Summary Star Gas Partners L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Teachers Insurance and Annuity Association of America (TIAA):企業の戦略・SWOT・財務情報
    Teachers Insurance and Annuity Association of America (TIAA) - Strategy, SWOT and Corporate Finance Report Summary Teachers Insurance and Annuity Association of America (TIAA) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆